REGV131-LNP1265

Gene therapy / editing

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)

Competitive landscape

This drug's own stage for Hemophilia B: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
REGV131-LNP1265: this drugPhase 1/2Gene therapy / editingFactor IXnot yet gradedNo reviewed efficacy summary in this indication
Etranacogene Dezaparvovec (Hemgenix)ApprovedGene therapy / editingFactor IX gene delivery (hFIX-Padua)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow REGV131-LNP1265 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2034 (1)
August 2034 (1)
Phase 1/2Hemophilia BRecruiting
Est. primary completion 2034-08-14 · NCT06379789 · CT.gov ↗
What to watch

See the full readout calendar ↗